Case report highlights the psychiatric side effects of GLP-1 receptor agonists in a patient with depression, suggesting caution in their use.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently emerged as a promising therapeutic option for patients to aid in weight loss; however, little is known about the potential psychiatric side effects of these medications. In this report, we present the case of a 64-year-old man who was started on the GLP-1 RA tirzepatide (Zepbound) and subsequently developed increased impulsivity, dysphoria, and aggression, which resolved with medication cessation. We suggest a potential relationship between GLP-1 RAs and mood, and we caution physicians to weigh the potential risks of the medications against the known benefits.
No takes yet. Share an insight, caveat, or question.
Hofstad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: